Trading Signals: AUTL Stock Price Prediction and Forecast (Fri. Jun. 22, 2018 - Fri. May. 13, 2022)(Autolus Therapeutics plc )
| AUTL latest price $3.7200 (-0.53%) ($3.7200 - $3.7200) on Fri. Jan. 28, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.11% (three month average) | RSI | 17 | Latest Price | $3.7200(-0.53%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | AUTL declines -1.3% a day on average for past five trading days. | Weekly Trend | AUTL declines -9.3% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support AUTL advance at 0% a week (0% probability) XBI(64%) IBB(58%) IBUY(56%) ARKG(52%) ARKK(51%) | Factors Impacting AUTL price | AUTL will decline at least -2.555% in a week (0% probabilities). VIXM(-40%) VXX(-32%) TLT(-25%) TIP(-25%) SHY(-23%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.555% (StdDev 5.11%) | Hourly BBV | -0.9 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-17.61(-573.39%) | Resistance Level | $4.39 | 5 Day Moving Average | $3.79(-1.85%) | 10 Day Moving Average | $3.97(-6.3%) | 20 Day Moving Average | $4.39(-15.26%) | To recent high | -47.2% | To recent low | 0% | Market Cap | $194m | | | | Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom. |